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Purpose: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic 
macular edema.
Methods: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal 
injection of 4 mg (n=12 eyes), 8 mg (n=17) or 25 mg (n=15) of triamcinolone acetonide (TA). Optical coherence 
tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, 
and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a 
range of 5-12 months.
Results: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing 
dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage.
Conclusions: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer 
after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg.
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Table 1. Demographics (mean±SD
*)
Male : Female 21 : 23
Age (year) 60±10
Follow-up period (month) 9.8±2.3
Macular thickness at baseline (μm) 559±228
LogMAR
† visual acuity at baseline 0.77±0.44
Intraocular pressure at baseline (mmHg)   14±2.5
*standard deviation; 
†the logarithm of the minimum angle of 
resolution.
Macular edema is the main cause of visual impairment in 
diabetic patients.
1 The Early Treatment Diabetic Retinopathy 
Study trial showed that focal laser photocoagulation is bene-
ficial for eyes with clinically significant diabetic macular 
edema.
2 However, the therapeutic value of scattered laser 
coagulation of the macula when capillary leakage and macular 
edema diffusely involve the posterior pole of the fundus has 
not been conclusively shown.
3
Recent investigations have reported the use of intravitreal 
triamcinolone acetonide (TA) for treatment of diffuse diabetic 
macular edema.
4,5 The exact mechanism of effects is not known, 
but triamcinolone is presumed to diminish retinal leakage and 
reduce retinal thickening in the macula, leading to improved 
visual acuity.
6
Different doses varying from about 4 mg to about 20 mg 
TA have been employed thus far. Whether efficacy and duration 
of the effect of intravitreal TA are dosage-dependent is unknown. 
Spandau et al.
7 reported that the efficacy of intravitreal TA was 
dosage-dependent, and treatment response lasted longer, and 
was more pronounced with increasing dosage.
The purpose of this study was to investigate the dosage- 
dependency of the duration and efficacy of intravitreal TA in 
the treatment of diffuse diabetic macular edema.
Materials and Methods
This clinical retrospective study included 44 eyes (40 
patients) with diabetic macular edema, defined according to 
the Early Treatment Diabetic Retinopathy Study (ETDRS). 
All patients were treated randomly with 4 mg, 8 mg, or 25 mg 
TA intravitreally, from 2004 June to 2005 May.
Assessment of diabetic macular edema was based on oph-
thalmoscopic examination, fluorescein angiography and OCT 
of the macula. The patients consisted of 19 men and 21 women 
with a mean age of 60 years (standard deviation [SD] 10; 
range 43-83 years). Mean follow-up was 9.8 months (SD 2.3; 
range 5-12 months). Macular thickness at baseline was 559 μm 
(SD 228; range 174-1263 μm). LogMAR visual acuity at 
baseline was 0.77 logMAR units (SD 0.44; range 0.2-2 units). 
Mean intraocular pressure (IOP) at baseline was 14 mmHg 
(SD 2.5; range 9-19 mmHg) (Table 1).
Treatment with TA was intravitreal, with 12 eyes (27%) JS Bae, et al. EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE
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Table 2. Baseline data of patients in each study group (mean±SD
*)
　 4 mg 8 mg 25 mg p-value
Number of eyes in group 12 17 15
Age  58.6±11.7 62.1±8.9 57.8±10.2 0.43
†
Follow up (months)  9.5±2.3 10.2±2.2 9.6±2.8 0.72
†
NPDR:PDR 9:3 7:10 9:6 0.19
‡
Preoperative macular thickness (μm)  566±213  564±222  545±259 0.97
†
Preoperative visual acuity (logMAR)  0.67±0.32  0.86±0.41  0.75±0.54 0.49
†
Preoperative intraocular pressure (mmHg) 13.3±1.9 13.6±2.9 14.0±2.5 0.16
†
*standard deviation; 
†analysis of variance (ANOVA); 
‡Chi-square test.
Table 3. Changes in macular thickness during follow-up (mean±SD
*)
Follow-up
4 mg 8 mg 25 mg
No. of
eyes
Differences
† of 
macular thickness 
(μm)
p-value
‡ No. of
eyes
Differences
† of 
macular thickness 
(μm)
p-value
‡ No of
eyes
Differences
† of 
macular 
thickness (μm)
p-value
‡
 1 month 12 347±203 0.002 17  351±203 0.001 15 363±239 0.001
 3 months 12 306±209 0.005 17  333±267 0.002 15 348±251 0.001
 6 months 11   80±173 0.345 16  246±212 0.003 10 333±310 0.018
 9 months 8 12±56 0.741 12 -52±92 0.225 6   77±112 0.265
12 months 6   7±42 0.712 9  -73±136 0.295 6 134±171 0.114
*standard deviation; 
†Differences between the preoperative and the postoperative macular thickness; 
‡Wilcoxon signed-rank test.
Fig. 1. Time course of macular thicknesses using OCT 3. Among 
the three groups, significant differences in macular thickness were 
seen at 6, 9 and 12 months (p=0.036, 0.028, 0.008 by ANOVA). In 
post-hoc tests, macular thickness in the 25 mg group was signi-
ficantly thinner than in the 4 mg group at 6 months, and the other 
two groups at 9 and 12 months (p<0.05 by Tukey).
receiving 4 mg, 17 (39%) receiving 8 mg, and 15 (34%) treated 
with 25 mg. No patients received reinjection. During follow-up, 
if ocular surgery or other ocular treatment of diabetic retino-
pathy had been performed, the patients were regarded as 
dropped at follow-up. All eyes included into the study received 
their last retinal laser treatment at least one month before 
inclusion into the study. If the criteria for retinal laser treatment 
according to the ETDRS study were fulfilled, laser treatment 
was performed. None of the eyes had received intravitreal 
injection before inclusion into the study. Randomization of 
patients into study groups was masked by the hospital pharmacy. 
The hospital pharmacy prepared the TA for intraocular 
injection by extracting 0.1 mL (for an intended dosage of 4 
mg) or 0.2 mL (for 8 mg) from a vial (Rheudenolone
Ⓡ, 40 
mg/mL Kukje pharmacy, Korea) containing 40 mg of TA in 1 
mL. The extracted volume was put into a tuberculin syringe 
(1 mL). An intended dosage of 25 mg was prepared from 0.1 
mL precipitate after erecting the syringe for 1 hour before 
extracting 1 mL from the vial. Concentrations were measured 
by High Phase Liquid Chromatography assay.
The extracted TA was injected into the vitreous after 
instillation of 0.5% propacaine hydrochloride (Alcaine
Ⓡ, Alcon, 
USA) and 5% povidone iodine. The injection was performed 
3.5 mm posterior to the limbus, through the inferior pars plana, 
with a 30-gauge needle. All patients were given levofloxacine 
drops (Cravit
Ⓡ, Santen, Japan) as a prophylactic treatment.
Visual acuity, macular thickness, and IOP baselines were 
determined at the beginning of the study. Macular thickness 
was measured by optical coherent tomography (OCT 3) 
(STRATUS-OCT Model 3000, Carl Zeiss Meditec Inc., San-
Leandro. CA) and IOP was measured by Goldmann applana-
tion tonometry (GAP). Visual acuity was determined in a 
standardized fashion by an observer performing best corrected 
refractometry, with measurements converted into the logarithm 
of the minimum angle of resolution (logMAR). Macular thick-
ness was determined manually with an OCT 3 measurement 
by a sophisticated examiner. IOP with GAP was measured by 
the same doctor. Visual acuity and IOP were re-examined the 
first day after the injection, then after 1 week and 1, 2, and 3 
months after the injection, and then at 3-month intervals. Korean J Ophthalmol Vol.23, No.2, 2009
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Table 4. Changes in visual acuity during follow-up (mean±SD
*)
Follow-up
4 mg 8 mg 25 mg
No. of eyes
Differences
† of 
visual acuity 
(logMAR)
p-value
‡ No. of eyes
Differences
† of 
visual acuity 
(logMAR)
p-value
‡ No. of eyes
Differences
† of 
visual acuity 
(logMAR)
p-value
‡
1 week 12   -0.21±0.12 0.005 17 -0.31±0.27 0.001 15 -0.21±0.46 0.007
1 month 12   -0.26±0.12 0.002 17 -0.29±0.27 0.002 15 -0.29±0.43 0.005
3 months 12   -0.27±0.19 0.003 17 -0.36±0.28 0.001 15 -0.38±0.48 0.001
6 months 11 +0.03±0.35 0.916 16 -0.28±0.26 0.007 10 -0.36±0.61 0.018
9 months 8 +0.03±0.06 0.314 12 -0.02±0.20 0.989 6 -0.08±0.09 0.181
12 months 6   -0.06±0.13 0.374 9 -0.12±0.29 0.414 6  0.30±0.65 0.31
*standard deviation; 
†Differences between the preoperative and the postoperative visual acuity; 
‡Wilcoxon signed-rank test.
Macular thickness was rechecked at 1, 3, 6, 9, and 12 months. 
Mean follow-up was 9.8 (SD 2.3) months (range 5-12 months).
Statistical analyses were performed using a commercially 
available statistical software package (SPSS
Ⓡ for Windows, 
version 12.0, SPSS, Chicago, IL, USA) for analysis of variance 
(ANOVA), chi-square test, Wilcoxon signed-rank test and 
Mann-Whitney test. The post-hoc test was done with Tukey 
analysis. The level of significance was 0.05 (two-sided) for 
all statistical testing.
Results 
In the first investigation, the 4 mg, 8 mg, and 25 mg study 
groups contained 12, 17, and 15 eyes, respectively, while in 
the final investigation, they contained 6, 9 and 6 eyes. Diag-
noses, ages, and follow-up periods were not significantly 
different among the three study groups (p=0.43, 0.51, 0.19), 
and there were no statistical differences in preoperative 
macular thickness, visual acuity, or IOP among three groups 
(p=0.97, 0.49, 0.16) (Table 2).
Macular thickness during follow-up
In the 4 mg study group, macular thickness decreased 
significantly (p=0.002) from 566 μm at baseline to a peak of 
218 μm at the 1-month follow-up. The thinnest region of 
macular thickness increased to a thickness of 653 μm at 12 
months after injection. After the 3-month follow-up, macular 
thickness differed significantly from the baseline value (p= 
0.005). Macular thickness at baseline (566 μm) and at the 
6-month follow-up (513 μm) did not differ significantly 
(p=0.345). Macular thickness at the 9-month follow-up (737 
μm) and the 12-month follow-up (653 μm) was thicker than 
at baseline (566 μm; p=0.741 for 9-month and p=0.712 for 
12-month; Table 3, Fig. 1).
In the 8 mg study group, macular thickness decreased 
significantly from 565 μm at baseline to a plateau of 213 μm 
(p=0.001) to 247 μm (p=0.002) at 1 and 3 months after injec-
tion. It increased to a value of 656 μm at 12 months after 
injection. Macular thickness obtained at the 6-month follow- 
up was significantly thinner than baseline (350 μm; p=0.003). 
Macular thickness at the 9-month (611 μm) and 12-month 
(656 μm) follow-ups was thicker than at baseline (565 μm 
p=0.225 and p=0.295; Table 3, Fig. 1).
In the 25 mg study group, macular thickness decreased 
significantly from 546 μm at baseline to a plateau between 
182 μm (p=0.001) at 1 month after injection, 197 μm (p= 
0.001) at 3 months after injection and 216 μm (p=0.018) at 6 
months after injection. At the 9-month and 12-month follow- 
ups, macular thicknesses were 309 and 314 μm, which were 
thinner than baseline (546 μm) but not significantly different 
(p=0.2650 for 9-months and p=0.114 for 12-months; Table 3, 
Fig. 1).
Among the three groups, there were significant differences in 
macular thickness at 6, 9 and 12 months. At 6 months, macular 
thickness was significantly different (p=0.036), especially 
between the 4 mg and 25 mg groups (p=0.028). At 9 months, 
macular thickness was significantly different (p=0.008), espe-
cially between the 4 mg and 25 mg group, and also between 
the 8 mg and 25 mg groups (p=0.009 and 0.029). At 12 months, 
comparison of macular thickness showed significant diffe-
rences among the three groups (p=0.002). The macular 
thickness of the 25 mg study group was significantly thinner 
than in the other groups at 9 and 12 months (p<0.05; Fig. 1).
Visual acuity during follow-up
In the 4 mg study group, increase in visual acuity was 
significantly (p=0.003), from 0.67 logMAR unit at baseline 
to a peak of 0.39 logMAR unit at the 3-month follow-up. 
From this peak value, it decreased to 0.66 at 12 months after 
injection. Visual acuity obtained at 1 week (0.46 logMAR unit), 
1 month  (0.41 logMAR unit) and 3 months (0.39 logMAR 
unit) differed significantly from the baseline visual acuity 
(p=0.005, 0.002, and 0.003). Visual acuity at 6, 9 and 12 months 
(0.73, 0.57, 0.66 logMAR unit) did not differ significantly 
from the baseline (0.67 logMAR unit; p=0.594, 0.115, 0.374; 
Table 4, Fig. 2).
In the 8 mg study group, increase in visual acuity was 
significant (p=0.001), from 0.86 logMAR unit at baseline to 
a peak of 0.51 logMAR unit at the 3-month follow-up. From 
this peak, it decreased to a value of 0.94 logMAR unit at 12 
months after injection. Visual acuity obtained at 1 week (0.55 
logMAR unit), 1 month (0.57 logMAR unit), 3 months (0.50 JS Bae, et al. EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE
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Fig. 2. Time course of logMAR visual acuities. Significant differ-
ences among the three groups were seen at the 9- and 12-month fol-
low-up (p<0.05 by ANOVA). The 25 mg study group showed sig-
nificantly better visual acuity than other two groups (p<0.05) by a 
post-hoc test.
Table 5. Changes in intraocular pressure during follow-up (mean±SD
*)
Follow-up
4 mg 8 mg 25 mg
No. of
eyes
Differences
† of 
pressure (mmHg) p-value
‡ No. of
eyes
Differences
† of 
pressure (mmHg) p-value
‡ No. of
eyes
Differences
† of 
pressure (mmHg) p-value
‡
 1 week 12 -0.3±3.1 0.758 17  0.7±2.3 0.752 15 1.1±3.4 0.305
 1 month 12  0.3±1.9 0.546 17  1.2±3.4 0.231 15 1.9±4.1 0.114
 3 months 12  1.0±2.7 0.234 17  2.2±3.1 0.015 15 3.9±4.6 0.008
 6 months 11 -0.7±2.5 0.395 16  1.6±3.7 0.139 10 5.1±9.1 0.171
 9 months 8  1.5±1.9 0.180 12  0.8±4.8 0.928 6 2.0±3.6 0.131
12 months 6  0.4±1.8 0.648 9 -0.8±4.0 0.68 6 0.6±2.2 0.50
*standard deviation; 
†Differences between the preoperative and the postoperative intraocular pressure; 
‡Wilcoxon signed-rank test.
Fig. 3. Time course of intraocular pressure. At 6, 9, and 12 months, 
significantly different results were obtained among the three groups 
(p=0.027, 0.025, 0.028 by ANOVA). Group 1 and 2 showed sig-
nificant differences (p=0.025, 0.027) at 6 and 12 months, and 
groups 1 and 3 showed differences (p=0.025) at 9-months by post- 
hoc test.
logMAR unit), and 6 months (0.66 logMAR unit) differed 
significantly from the baseline (p=0.001, 0.002, 0.001, and 
0.007). Visual acuity at the 9 and 12 month follow-ups (0.88, 
0.94 logMAR unit) did not differ significantly from the 
baseline (p=0.989, 0.414; Table 4, Fig. 2).
In the 25 mg study group, visual acuity increased signifi-
cantly (p=0.018) from 0.75 logMAR unit at baseline to a peak 
of 0.37 logMAR unit at the 3-month follow-up. From this 
peak, it decreased to a value of 0.48 logMAR unit at 12 months 
after injection. Visual acuity at 1 week (0.54 logMAR unit), 1 
month (0.39 logMAR unit), 3 months (0.37 logMAR unit), 
and 6 months (0.39 logMAR unit) differed significantly from 
the baseline (p=0.007, 0.005, 0.001, and 0.018). Visual acuity at 
the 9- and 12- month follow-ups (0.42, 0.48 logMAR unit) 
did not differ significantly from the baseline (p=0.181, 0.310; 
Table 4, Fig. 2).
At 9 and 12 months, visual acuity showed significant 
differences between the three groups (p=0.016, 0.002). At 9 
and 12 months, comparisons between the 4 mg and 25 mg 
group, and also between the 8 mg and 25 mg groups showed 
significant differences (p<0.05), with the 25 mg group having 
better visual acuity (Fig. 2).
IOP during follow-up
In the 4 mg study group, IOP increased slightly, from 13.7 
mmHg at baseline to a peak of 14.7 mmHg at the 3-month 
follow-up, however the change was not statistically signi-
ficant (p=0.232). From the peak value, it decreased to 12.2 
mmHg at 12 months after injection. IOP obtained through the 
follow-up period did not differ significantly from the baseline 
(Table 5, Fig. 3).
In the 8 mg study group, IOP increased from 13.7 mmHg 
at baseline to a peak of 15.8 mmHg at the 3-month follow-up 
and the change was statistically significant (p=0.015). From 
the peak value, it decreased to 15.4 mmHg at 12 months after 
injection. IOP measurements obtained through the follow-up 
period did not differ significantly from the baseline IOP, 
except at 3 months (Table 5, Fig. 3).
In the 25 mg study group, IOP increased from 15.0 mmHg 
at baseline to a peak of 19.9 mmHg at the 6-month follow-up, 
but the change was not statistically significant (p=0.171). 
From the peak value, it decreased to 14.5 mmHg at 12 months 
after injection. IOP obtained through the follow-up period 
did not differ significantly from the baseline (Table 5, Fig. 3).Korean J Ophthalmol Vol.23, No.2, 2009
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Table 6. Elevated intraocular pressure during follow-up (mean±SD
*)
　 4 mg 8 mg 25 mg p-value
Number of eyes 12 17 15
Mean highest IOP
† (mmHg) 16.7±2.2 17.8±2.4 22.8±6.8 0.001
‡
Highest IOP
†
below 22 mmHg 12 15 7 0.002
§
22-30 mmHg 0 2 6
above 30 mmHg 0 0 2
Eyes with antiglaucoma medication 0 1 6
Mean number of antiglaucoma medication 0 1   1.5±0.8 0.600
П
Mean duration of antiglaucoma medication (months) 0 2   2.8±1.7 0.533
П
*standard deviation; 
†intraocular pressure; 
‡analysis of variance (ANOVA); 
§Chi-square test; 
ПMann-Whitney test.
At 6, 9, and 12 months, significant differences in IOP were 
seen among the three groups (p=0.027, 0.025, 0.028; Fig. 3). 
In particular, analysis of the 4 mg and 8 mg groups showed 
significant differences at 6 and 12 months (p=0.025, 0.027). 
Analysis of the 4 mg and 25 mg groups showed differences 
(p=0.025) at 9 months (Fig. 3).
The mean highest intraocular pressures during follow-up 
were 16.7 mmHg (4 mg study group), 17.8 mmHg (8 mg study 
group), and 22.8 mmHg (25 mg study group). IOP in the 25 
mg study group was significantly higher than that of the other 
groups (p=0.001). The number of eyes for which the highest 
IOP measured below 22 mmHg in each group were 12, 15, 
and 7 respectively (p=0.002). The number of eyes for which 
the highest IOP ranged from 22 mmHg to 30 mmHg was 2 of 
17 in the 8 mg study group, 6 of 15 in the 25 mg study group 
and none in the 4 mg study group. The number of eyes for which 
the highest IOP measured above 30 mmHg was 2 of 15 in the 
25 mg study group. Antiglaucoma medication was not needed 
in the 4 mg study group, but required in the 8 and 25 mg study 
groups. The number of eyes that required antiglaucoma medi-
cation was 1 of 17 in the 8 mg study group and 6 of 15 in the 
25 mg study group. The mean number receiving antiglaucoma 
medications was 1 in the 8 mg study group and 1.5 in the 25 
mg study group (p=0.6). The mean duration of antiglaucoma 
medication was 2 months in the 8 mg study group and 2.8 
monthsin the 25 mg study group (p=0.533).
Discussion
Recent studies have suggested that intravitreal TA may be 
useful for increasing visual acuity in patients with diffuse 
diabetic macular edema.
8,9 In previous studies, the effect of 
intravitreal TA was studied using follow-up periods of up to 6 
months. Jonas et al.
10 observed a significant improvement in 
visual acuity up to 6 months after injection of 25 mg TA. 
Martidis et al.
11 injected a lower dose (4 mg) and reported a 
visual improvement and a reduction in macular thickness of 
58% and 38% at 3 and 6 months, respectively. On the other 
hand, Massin et al.,
8 also using 4 mg TA, found no significant 
beneficial effect on visual acuity, although a significant 
reduction in macular thickness was observed using OCT, 
until 3 months. Recently, Jonas et al.
10,12 reported favorable 
results with a higher dose of TA (25 mg).
Using a dosage of about 20 mg, the increase in visual 
acuity was most marked for the first 3-6 months after the 
injection, and was present during a period of about 6-9 
months.
12 At 4 mg, the duration of the effect, as measured by 
a reduction in macular thickness by optical coherence tomo-
graphy, was less than 6 months.
8,11 At the end of follow-up, 
visual acuity measurements often returned to baseline values 
with no significant difference between the final baseline 
values.
8,11 These investigations, which indirectly compare the 
duration of the effect of intravitreal TA, have been confirmed 
by the present study.
This study showed that the duration of intravitreal TA 
effect on macular thickness increased with increasing dosage 
(Table 3). The 8 mg study group showed effects similar to the 
25 mg study group through the 6-month follow-up. Interes-
tingly, in the 25 mg study group, macular thickness at the 9- 
and 12-month follow-ups (309 μm), was thinner than at baseline 
(546 μm), although not significantly so. In this period, the 4 
mg and 8 mg study groups showed thicker macular thickness 
than baseline (Table 3, Fig. 1).
The duration of the TA effect on visual acuity increased 
with increasing dosage (Table 4). The 8 mg study group did 
not differ from 25 mg study group through the 6-month follow 
up. Interestingly, visual acuities in both the 4 mg and 25 mg 
study groups at the 9- and 12-month follow-up were higher 
but not significantly increased from the baseline visual acuity 
(Table 4, Fig. 2).
These data may suggest that for at least 6 months, the 
amount of post-injection increase in visual acuity and the 
duration of the effect of intravitreal TA show a dosage depen-
dency, which is lost after 6 months. This may have implications 
for discussions on the dosage of intravitreal TA to be used as 
treatment for diffuse diabetic macular edema, and on how to 
reduce the frequency of required intravitreal reinjections. 
Future studies are necessary to evaluate the optimum dosage 
with regard to tolerability, side effects, and duration of action.
The main side effect of intravitreal TA observed in the present 
study was an increase in IOP. Consistent with previous 
studies,
13-15 the secondary ocular hypertension could usually JS Bae, et al. EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE
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be treated with topical antiglaucoma medication without the 
development of glaucomatous optic nerve damage. Ten (23%) 
eyes developed maximal IOP measurements higher than 21 
mmHg. The mean highest IOP during follow-up was signifi-
cantly higher in the 25 mg study group than in both the 4 mg 
and 8 mg groups (Table 6). This suggests that the possibility 
of high dosages of intravitreal TA leading to IOP elevation 
must be taken into account. These results are different from 
previous independent investigations, in which the frequency 
of elevated IOP after the intravitreal injection of TA did not 
vary between studies using a dosage of 4 mg compared with 
studies using a dosage of about 20 mg.
14,16
Other than the side effect of elevated IOP, none of the 
study groups showed infection, or a marked progression of 
cataracts as assessed by slitlamp biomicroscopy.
17-21 The 
study sample, however, may have been too small to statistically 
address these questions, since most side effects such as infec-
tious endophthalmitis, may have a frequency of less than 1%.
A limitation of the study might be that, although intravitreal 
TA increased the degree of cataracts, cataract surgery was not 
performed in combination with, or after, the intravitreal 
injection of TA during follow-up. The vision-reducing effect 
of progressive cataracts might have hidden some of the 
vision-improving effects of TA. Another limiting factor of 
this study might be the relatively small number of patients 
and the decrease in the number of those patients after the 6- 
month follow-up. Nonetheless, the postinjection increase in 
visual acuity, as well as the duration of the effect, were larger 
in both the 8 mg and 25 mg study group than in the 4 mg 
study group.
In conclusion, these data suggest that treatment response 
may last longer with a dose of 8 or 25 mg TA compared to a 
dose of 4 mg, in patients with diffuse diabetic macular edema. 
The increase in intraocular pressure induced by TA may not 
be strictly associated with the dosage used.
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